

DELEAGE JEAN

Form 4

February 18, 2011

FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
ACP IV, L.P.

2. Issuer Name **and** Ticker or Trading
Symbol
ACELRX PHARMACEUTICALS
INC [ACRX]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
ONE EMBARCADERO CENTER,
SUITE 3700,

3. Date of Earliest Transaction
(Month/Day/Year)
02/16/2011

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

(Street)
SAN FRANCISCO, CA 94111

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/16/2011		C		682,904	A	<u>(1)</u>	682,904	D	<u>(2)</u>
Common Stock	02/16/2011		C		328,064	A	<u>(3)</u>	1,010,968	D	<u>(2)</u>
Common Stock	02/16/2011		C		810,129	A	<u>(4)</u>	1,821,097	D	<u>(2)</u>
Common Stock	02/16/2011		C		279,097	A	<u>(5)</u>	2,100,194	D	<u>(2)</u>
Common Stock	02/16/2011		C		14,713	A	<u>(4)</u>	2,114,897	D	<u>(2)</u>

Edgar Filing: DELEAGE JEAN - Form 4

Common Stock 02/16/2011 P 680,000 A \$ 5 2,794,907 D (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount
Series A Convertible Preferred Stock	<u>(1)</u>	02/16/2011		C	500,000	<u>(6)</u> <u>(7)</u>	Common Stock 680,000
Series B Convertible Preferred Stock	<u>(3)</u>	02/16/2011		C	218,750	<u>(6)</u> <u>(7)</u>	Common Stock 320,000
Series C Convertible Preferred Stock	<u>(4)</u>	02/16/2011		C	810,129	<u>(6)</u> <u>(7)</u>	Common Stock 810,129
Convertible Promissory Notes	<u>(8)</u>	02/16/2011		J	\$ 644,556	<u>(9)</u> <u>(9)</u>	Common Stock 100,000
Warrant to Purchase Series C Convertible Preferred Stock	<u>(8)</u>	02/16/2011		J	40,865	<u>(10)</u> <u>(11)</u>	Series C Preferred 40,865
Convertible Promissory Notes	<u>(5)</u>	02/16/2011		C	\$ 1,097,487	<u>(5)</u> <u>(5)</u>	Common Stock 270,000
Warrant to Purchase Series C	<u>(10)</u>	02/16/2011		X	69,588	<u>(10)</u> <u>(12)</u>	Series C Preferred 69,588

Convertible
Preferred
Stock

Series C
Convertible
Preferred
Stock

(4)

02/16/2011

X

69,588
(13)

(6)

(7)

Common
Stock

6

Series C
Convertible
Preferred
Stock

(4)

02/16/2011

S

54,875 (13)

(6)

(7)

Common
Stock

5

Series C
Convertible
Preferred
Stock

(4)

02/16/2011

C

14,713

(6)

(7)

Common
Stock

1

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ACP IV, L.P. ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		X		
NOHRA GUY P ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111	X	X		
JANNEY DANIEL ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		X		
DELEAGE JEAN ONE EMBARCADERO CENTER 37TH FLOOR SAN FRANCISCO, CA 94111		X		
Mack David Henry ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		X		
ACMP IV LLC ONE EMBARCADERO CENTER, SUITE 3700 SAN FRANCISCO, CA 94111		X		

Signatures

/s/ by ACMP IV, LLC, by Guy Nohra,
Director

02/18/2011

Edgar Filing: DELEAGE JEAN - Form 4

__Signature of Reporting Person	Date
/s/ Guy Nohra	02/18/2011
__Signature of Reporting Person	Date
/s/ Daniel Janney	02/18/2011
__Signature of Reporting Person	Date
/s/ Jean Deleage	02/18/2011
__Signature of Reporting Person	Date
/s/ David Mack	02/18/2011
__Signature of Reporting Person	Date
/s/ by Guy Nohra, Director	02/18/2011
__Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares reflect the automatic conversion of 500,000 shares of the Issuer's Series A Preferred Stock for 682,904 shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.
ACMP IV, LLC ("ACMPIV") is the general partner of ACP IV, L.P. ("ACPIV") Jean Deleage, Daniel Janney, David Mack, and Guy Nohra are directors of ACMPIV and may be deemed to share voting and dispositive power with respect to all securities of the Issuer held by ACPIV. Guy Nohra is also a director of the Issuer. Mr. Deleage, Mr. Janney, Mr. Mack, and Mr. Nohra disclaim beneficial ownership of such securities except to the extent of his proportionate pecuniary interest therein.
- (2) The shares reflect the automatic conversion of 218,750 shares of Series B Preferred Stock for 328,064 shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.
- (3) The shares reflect the automatic conversion of shares of the Issuer's Series C Preferred Stock into Common Stock on a one-to-one basis upon the closing of the Issuer's initial public offering.
- (4) Notes and accrued interest in the aggregate of \$1,116,388.59 converted automatically upon the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price of \$4.00, which is 80% of the per share price of the Common Stock sold in the Issuer's initial public offering.
- (5) Immediately convertible into shares of the Issuer's Common Stock.
- (6) These shares have no expiration date.
- (7) Pursuant to Note and Warrant Transfer Agreement dated February 16, 2011, ACP IV, L.P. transferred (i)a convertible promissory note in the amount of \$655,656.79 including accrued interest and (ii)an associated warrant to purchase preferred stock on the Issuer, exercisable into 40,865 shares of Series C Preferred Stock.
- (8) Principal amount plus interest converts automatically upon the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price of \$4.00, which is 80% of the per share price of the Common Stock sold in the Issuer's initial public offering.
- (9) The exercise price is \$3.9428 per share and immediately exercisable prior to and contingent upon the closing of the Issuer's initial public offering.
- (10) Pursuant to its terms, warrant would terminate at the closing of the Issuer's initial public offering. In the event the Issuer's public offering did not occur, the warrant would have terminated on September 14, 2017, unless earlier terminated in accordance with its terms, in a liquidation or change of control transaction.
- (11) Pursuant to its terms, warrant shall terminate at the closing of the Issuer's initial public offering. Holder has elected to net exercise the warrants contingent upon and effective immediately prior to the closing of the Issuer's initial public offering of common stock.
- (12) These shares reflect the net exercise of the Series C warrant pursuant to the terms of the warrant into 14,713 shares of the Issuer's Series C Preferred Stock.
- (13)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.